Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

SGLT2 inhibitors: further evidence for heart failure with preserved ejection fraction as a metabolic disease?
Justin B. Echouffo-Tcheugui, … , Sabra C. Lewsey, Robert G. Weiss
Justin B. Echouffo-Tcheugui, … , Sabra C. Lewsey, Robert G. Weiss
Published December 1, 2021
Citation Information: J Clin Invest. 2021;131(23):e156309. https://doi.org/10.1172/JCI156309.
View: Text | PDF
Viewpoint Article has an altmetric score of 6

SGLT2 inhibitors: further evidence for heart failure with preserved ejection fraction as a metabolic disease?

  • Text
  • PDF
Abstract

Authors

Justin B. Echouffo-Tcheugui, Sabra C. Lewsey, Robert G. Weiss

×

Total citations by year

Year: 2025 2024 2023 2022 Total
Citations: 2 2 1 2 7
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article (7)

Title and authors Publication Year
The Heart Has Intrinsic Ketogenic Capacity that Mediates NAD+ Therapy in HFpEF
Koay YC, McIntosh B, Ng YH, Cao Y, Wang XS, Han Y, Tomita S, Bai AY, Hunter B, Misra A, Loughrey CM, Bannon PG, Lal S, Lusis AJ, Kaye DM, Larance M, O\u2019Sullivan JF
Circulation Research 2025
Efficacy of Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors in Heart Failure With Preserved Ejection Fraction: A Systematic Review
Santos Guzmán MV, Rivera D, Reyna Guerrero IM, Fernandez Rodriguez AL, Azcona R, Escobar Batista D, Montano Diaz G, García Zuluaga LC, Santos Rosario V
Cureus 2025
Cardiac Substrate Utilization and Relationship to Invasive Exercise Hemodynamic Parameters in HFpEF
O\u2019Sullivan JF, Li M, Koay YC, Wang XS, Guglielmi G, Marques FZ, Nanayakkara S, Mariani J, Slaughter E, Kaye DM
JACC: Basic to Translational Science 2024
Empagliflozin Improves Diastolic Function in HFpEF by Restabilizing the Mitochondrial Respiratory Chain
Schauer A, Adams V, Kämmerer S, Langner E, Augstein A, Barthel P, Männel A, Fabig G, Alves PK, Günscht M, El-Armouche A, Müller-Reichert T, Linke A, Winzer EB
Circulation. Heart failure 2024
Emerging concepts in heart failure management and treatment: focus on SGLT2 inhibitors in heart failure with preserved ejection fraction
De Lorenzi AB, Kaplinsky E, Zambrano MR, Chaume LT, Rosas JM
Drugs in Context 2023
Proteomic and phosphoproteomic profiling in heart failure with preserved ejection fraction (HFpEF).
Valero-Muñoz M, Saw EL, Hekman RM, Blum BC, Hourani Z, Granzier H, Emili A, Sam F
Frontiers in Cardiovascular Medicine 2022
The Role of Sodium-Glucose Cotransporter-2 Inhibition in Heart Failure with Preserved Ejection Fraction.
Brust-Sisti L, Rudawsky N, Gonzalez J, Brunetti L
2022

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Posted by 10 X users
16 readers on Mendeley
See more details